Search research articles
Contact Us
Filters
Showing results (41-50 of 366) with videos related to
Page
of 37
Sort By:
JAMA Oncology
|
March 13, 2025
Sotorasib's Accelerated Approval: Wrong Dose and Indication
Mark J Ratain, Aaron S Kesselheim
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 5, 2025
Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer
Mark J Ratain, Antonio Tito Fojo
Clinical Pharmacology and Therapeutics
|
April 6, 2019
Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew
Garth W Strohbehn, Mark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2012
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?
Lionel D Lewis, Mark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2018
Time Is Money: Optimizing the Scheduling of Nivolumab
Mark J Ratain, Daniel A Goldstein
European Journal of Cancer (Oxford, England : 1990)
|
October 8, 2023
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
Mark J Ratain, Garth W Strohbehn
JTO Clinical and Research Reports
|
July 3, 2026
Ivonescimab: The Next United States Food and Drug Administration Project Optimus Flashpoint?
Garth W Strohbehn, Mark J Ratain
Clinical Pharmacology and Therapeutics
|
April 8, 2022
Lorlatinib Exposed: A Far From Optimal Dose
Garth W Strohbehn, Mark J Ratain
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|
April 9, 2005
EGFR pharmacogenomics: the story continues to mutate and evolve
Apurva A Desai, Mark J Ratain
Mayo Clinic Proceedings
|
February 5, 2013
Preventing adverse drug-drug interactions: a need for improved data and logistics
Michael J Seminerio, Mark J Ratain
Page
of 37
Search research articles
Search
Showing results (41-50 of 366) with videos related to
Sort By:
Page
of 37
JAMA Oncology
|
March 13, 2025
Sotorasib's Accelerated Approval: Wrong Dose and Indication
Mark J Ratain, Aaron S Kesselheim
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 5, 2025
Opportunities for Harmonization of US Food and Drug Administration Regulatory Decisions Exemplified by the Traditional Approval of Sotorasib and Panitumumab for Colorectal Cancer
Mark J Ratain, Antonio Tito Fojo
Clinical Pharmacology and Therapeutics
|
April 6, 2019
Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew
Garth W Strohbehn, Mark J Ratain
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2012
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?
Lionel D Lewis, Mark J Ratain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 28, 2018
Time Is Money: Optimizing the Scheduling of Nivolumab
Mark J Ratain, Daniel A Goldstein
European Journal of Cancer (Oxford, England : 1990)
|
October 8, 2023
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
Mark J Ratain, Garth W Strohbehn
JTO Clinical and Research Reports
|
July 3, 2026
Ivonescimab: The Next United States Food and Drug Administration Project Optimus Flashpoint?
Garth W Strohbehn, Mark J Ratain
Clinical Pharmacology and Therapeutics
|
April 8, 2022
Lorlatinib Exposed: A Far From Optimal Dose
Garth W Strohbehn, Mark J Ratain
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|
April 9, 2005
EGFR pharmacogenomics: the story continues to mutate and evolve
Apurva A Desai, Mark J Ratain
Mayo Clinic Proceedings
|
February 5, 2013
Preventing adverse drug-drug interactions: a need for improved data and logistics
Michael J Seminerio, Mark J Ratain
Page
of 37